InnoCare
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel small molecule therapies for oncology and immunology.
OncologyImmunology
Technology Platform
Integrated drug discovery and development platform focused on structure-based rational drug design for small molecules targeting key disease pathways.
Opportunities
Significant opportunity to expand orelabrutinib's label into autoimmune diseases and advance its pipeline of novel targeted therapies in global markets.
Risk Factors
Clinical and commercial risks include pipeline setbacks, intense competition in core areas, and pricing pressures in the Chinese market.
Competitive Landscape
Faces intense competition in oncology (e.g., from BeiGene) and immunology from both global pharma and a crowded field of Chinese biotechs developing BTK and other kinase inhibitors.